Sareum Holdings PLC Sareum to Present at BIO Digital 2020
27 Maggio 2020 - 8:00AM
RNS Non-Regulatory
TIDMSAR
Sareum Holdings PLC
27 May 2020
27 May 2020
Sareum Holdings PLC
("Sareum" or the "Company")
Sareum to Present at BIO Digital 2020
Sareum Holdings plc (AIM:SAR) , the specialist drug development
company delivering targeted small molecule therapeutics to improve
the treatment of cancer and autoimmune diseases , announces that
its CEO, Dr Tim Mitchell, will give a Company presentation at BIO
Digital 2020, which will be delivered on-line from 8-12 June
2020.
The presentation will highlight Sareum's two proprietary
TYK2/JAK1 kinase inhibitor programmes, SDC-1801 and SDC-1802,
targeting autoimmune diseases and cancers, respectively. Dr
Mitchell will also outline the emerging potential of this mechanism
to modulate the severe inflammatory responses and respiratory
symptoms arising from coronavirus and other viral infections.
The presentation will be made through the BIO Digital website
and will be available on demand to registered participants during
the conference - www.bio.org/events/bio-digital/sessions/685707
.
A copy of the presentation will also be made available on
Sareum's website - www.sareum.co.uk . The Company's website has
also been updated to include information on the potential of its
SDC-1801 TYK2/JAK1 inhibitor in the fight against Covid-19 -
www.sareum.com/discovery/tyk2jak1-covid19/ .
For 2020, the BIO International Convention will transition to a
new, virtual event format, BIO Digital. This virtual gathering of
the global biotech industry provides access to key partners via BIO
One-on-One Partnering, educational resources to help drive
participant's businesses, and the insights needed to continue
critical research and development.
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497 700
Strand Hanson Limited (Nominated Adviser)
James Dance / Richard Tulloch 020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce / John Beresford-Peirse 020 3764 2341
Citigate Dewe Rogerson (Financial PR)
Mark Swallow / David Dible 020 7638 9571
About Sareum
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics to improve the treatment of
cancer and autoimmune disease. The Company aims to generate value
through licensing its candidates to international pharmaceutical
and biotechnology companies at the preclinical or early clinical
trials stage.
Sareum is advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through
preclinical development as therapies for autoimmune diseases,
including the "cytokine storm" immune system overreaction to
Covid-19 and other viral infections, (SDC-1801) and cancer
immunotherapy (SDC-1802). The Company is targeting completion of
preclinical development for each molecule in 2020.
The Company's preclinical FLT3+Aurora inhibitor programme
targeting haematological cancers is licensed to a China-based
specialty pharma company.
Sareum also has an economic interest in SRA737, a clinical-stage
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets
cancer cell replication and DNA damage repair mechanisms.
Preliminary data suggest SRA737 may have broad application in
combination with other oncology and immune-oncology drugs in
genetically defined patients.
SRA737 was discovered and initially developed by scientists at
The Institute of Cancer Research in collaboration with Sareum, and
with funding from Sareum and Cancer Research UK. SRA737 was
licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc., which
is currently seeking to on-license SRA737 to a third party for
further development.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at
www.sareum.co.uk.
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABLGDUDDDDGGL
(END) Dow Jones Newswires
May 27, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Sareum (LSE:SAR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Sareum (LSE:SAR)
Storico
Da Apr 2023 a Apr 2024
